Sort   by:  
 Page size 
UnknownPhase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sezary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
Not available
S-EPMC5089160 | biostudies-literature
UnknownBruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Not available
S-EPMC5505166 | biostudies-literature
UnknownBrentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
Not available
S-EPMC4171358 | biostudies-literature
UnknownRandomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.
Not available
S-EPMC4451176 | biostudies-literature
UnknownGene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma.
Not available
S-EPMC3574267 | biostudies-literature
Sort   by:  
 Page size